Cargando…

Tyrosine kinase signaling-independent MET-targeting with CAR-T cells

BACKGROUND: Recent progress in cancer immunotherapy encourages the expansion of chimeric antigen receptor (CAR) T cell therapy in solid tumors including hepatocellular carcinoma (HCC). Overexpression of MET receptor tyrosine kinase is common in HCC; however, MET inhibitors are effective only when ME...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qin, Anna, Qin, Yuan, Lee, Joseph, Musket, Anna, Ying, Mingyao, Krenciute, Giedre, Marincola, Francesco M., Yao, Zhi Q., Musich, Phillip R., Xie, Qian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544186/ https://www.ncbi.nlm.nih.gov/pubmed/37779207 http://dx.doi.org/10.1186/s12967-023-04521-9

Ejemplares similares

Receptor tyrosine kinases as druggable targets in glioblastoma: Do signaling pathways matter?
por: Qin, Anna, et al.
Publicado: (2021)

Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody
por: Kou, Jianqun, et al.
Publicado: (2018)

Next Generation CAR T Cells for the Immunotherapy of High-Grade Glioma
por: Petersen, Christopher T., et al.
Publicado: (2019)

Hypoxia-inducible CAR expression: An answer to the on-target/off-tumor dilemma?
por: Prinzing, Brooke, et al.
Publicado: (2021)

Steering CAR T cell epigenetic programs by tweaking manufacturing protocol
por: Dukes, Meghan W., et al.
Publicado: (2023)

Chimeric antigen receptor T-cell therapy in glioblastoma: charging the T cells to fight
por: Land, Craig A., et al.
Publicado: (2020)

Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma
por: Yi, Zhongzhen, et al.
Publicado: (2018)

EPEN-04. DEVELOPMENT OF B7-H3-TARGETED CAR T CELL THERAPY FOR EPENDYMOMA
por: Mehta, Sanya, et al.
Publicado: (2023)

MyD88/CD40 signaling retains CAR T cells in a less differentiated state
por: Prinzing, Brooke, et al.
Publicado: (2020)

MDB-20. IMPROVING THE PERSISTENCE OF CAR T CELLS AGAINST GROUP 3 MEDULLOBLASTOMAS VIA EPIGENETIC REGULATION OF EXHAUSTION
por: Dukes, Meghan, et al.
Publicado: (2023)

Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
por: Yao, Yu, et al.
Publicado: (2023)

Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor
por: Fujino, Toshio, et al.
Publicado: (2021)

Overexpression of HGF/MET axis along with p53 inhibition induces de novo glioma formation in mice
por: Qin, Yuan, et al.
Publicado: (2020)

Receptor tyrosine kinase Met promotes cell survival via kinase-independent maintenance of integrin α3β1
por: Tesfay, Lia, et al.
Publicado: (2016)

IMMU-05. B7-H3-SPECIFIC CAR T CELLS HAVE POTENT ANTI-TUMOR ACTIVITY IN THE GL261 IMMUNE-COMPETENT MURINE BRAIN TUMOR MODEL
por: Haydar, Dalia, et al.
Publicado: (2020)

HGF-independent regulation of MET and GAB1 by nonreceptor tyrosine kinase FER potentiates metastasis in ovarian cancer
por: Fan, Gaofeng, et al.
Publicado: (2016)

Origin and evolution of plexins, semaphorins, and Met receptor tyrosine kinases
por: Junqueira Alves, Chrystian, et al.
Publicado: (2019)

DIPG-34. IMMUNE SYNAPSE OPTIMIZED GRP78-SPECIFIC CAR T CELLS ELICIT AN IMPROVED ANTITUMOR RESPONSE AGAINST DIPGS
por: Ibanez, Jorge, et al.
Publicado: (2023)

Charachterization and functional analysis of scFv-based CARs to redirect T cells to IL13Rα2-positive glioma
por: Krenciute, Giedre, et al.
Publicado: (2015)

CD47 expression is critical for CAR T-cell survival in vivo
por: Beckett, Alex N, et al.
Publicado: (2023)

Caspase-generated fragment of the Met receptor favors apoptosis via the intrinsic pathway independently of its tyrosine kinase activity
por: Lefebvre, J, et al.
Publicado: (2013)

Oncogenic mechanism-based pharmaceutical validation of therapeutics targeting MET receptor tyrosine kinase
por: Yao, Hang-Ping, et al.
Publicado: (2021)

Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607
por: Dai, Yao, et al.
Publicado: (2012)

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia
por: Kentsis, Alex, et al.
Publicado: (2012)

Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma
por: Demkova, Lucia, et al.
Publicado: (2018)

AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis
por: Choi, Yun Jung, et al.
Publicado: (2019)

MET Receptor Tyrosine Kinase Regulates Lifespan Ultrasonic Vocalization and Vagal Motor Neuron Development
por: Kamitakahara, Anna K., et al.
Publicado: (2021)

MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma
por: Catenacci, Daniel V. T., et al.
Publicado: (2016)

Tyrosine Kinase c-MET as Therapeutic Target for Radiosensitization of Head and Neck Squamous Cell Carcinomas
por: Lüttich, Lina, et al.
Publicado: (2021)

IMMU-01. Combining CD28 and 4-1BB costimulationin trans enhances the anti-glioma efficacy and persistence of B7-H3 CAR T cells in immune-competent brain tumor models
por: Haydar, Dalia, et al.
Publicado: (2022)

Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities
por: Zhang, Yazhuo, et al.
Publicado: (2018)

Proteolytic cleavages of MET: the divide-and-conquer strategy of a receptor tyrosine kinase
por: Fernandes, Marie, et al.
Publicado: (2019)

Expression and Prognostic Evaluation of the Receptor Tyrosine Kinase MET in Canine Malignant Melanoma
por: Koo, Karen, et al.
Publicado: (2023)

Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer
por: Hu, Chen-Yu, et al.
Publicado: (2019)

IMMU-01. EVALUATING THE IMPACT OF CAR DESIGN ON THE TUMOR IMMUNE MICROENVIRONMENT AND ANTI-TUMOR RESPONSE IN SYNGENEIC GLIOMA MODELS
por: Haydar, Dalia, et al.
Publicado: (2023)

The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells
por: Welsh, James W, et al.
Publicado: (2009)

A new synaptic player leading to autism risk: Met receptor tyrosine kinase
por: Judson, Matthew C., et al.
Publicado: (2011)

Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma
por: Zhao, Yuanyuan, et al.
Publicado: (2015)

c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma
por: Granito, Alessandro, et al.
Publicado: (2015)

The c-MET receptor tyrosine kinase contributes to neutrophil-driven pathology in cutaneous leishmaniasis
por: Passelli, Katiuska, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kumd7afrherj0dl4gqrcnuk1g4